Section Arrow
TENX.NASDAQ
- Tenax Therapeutics
Quotes are at least 15-min delayed:2026/04/17 04:20 EDT
Pre Market
Last
 --
-- (--)
Bid
13.27
Ask
17
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 13.48
-0.53 (-3.78%)
Day High 
14.91 
Prev. Close
14.01 
1-M High
16.95 
Volume 
534.87K 
Bid
13.27
Ask
17
Day Low
13.28 
Open
14.05 
1-M Low
13.22 
Market Cap 
240.94M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.82 
20-SMA 14.72 
50-SMA 13.49 
52-W High 18.38 
52-W Low 4.63 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.34/-1.37
Enterprise Value
240.94M
Balance Sheet
Book Value Per Share
5.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PBMPsyence Biomedical Ltd.5.87+2.99+103.82%-- 
Pre Market 11.6258 +5.7558 +98.05%
IMMPImmutep Limited0.5796+0.0356+6.54%-- 
Pre Market 0.543 -0.0366 -6.31%
ALLOAllogene Therapeutics2.37+0.2+9.22%-- 
Pre Market 2.3742 +0.0042 +0.18%
ASBPAspire Biopharma Holdings Inc.0.3-0.2449-44.94%-- 
Pre Market 0.3 0 0.00%
IBRXImmunityBio7.25-0.53-6.81%-- 
Pre Market 7.27 +0.02 +0.28%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.